Charlson comorbidity index

Charlson comorbidity index

(charl′sŏn)
[Mary E. Charlson, contemporary U.S. internist and epidemiologist]
A prognostic tool that estimates the likelihood that a person with particular illnesses will survive for a specified number of years. The index, which takes into account the patient's age and illnesses such as heart, lung, endocrine, kidney, or blood disorders, can also be used to estimate the resource utilization of patients with a variety of chronic diseases.
References in periodicals archive ?
The age, gender, main causes of ESRD, blood pressure, height, weight, body mass index (BMI), biochemical examination, and the Charlson comorbidity index (CCI) scores of urgent-start PD patients were recorded.
As an example, LACE (Length of stay, Acuity of admission, Charlson comorbidity index, and number of Emergency visits in preceding 6 months) can quantify the risk of death or unplanned readmissions and is used throughout the world to predict 30-day readmissions.
We collected the following clinical data using electronic medical records: age-adjusted Charlson comorbidity index (20), sex, sites of specimen collection, date of specimen collection, date of patient death, pulse rate, oxygen saturation, body temperature, chest radiograph results, and any antimicrobial agents administered during hospitalization.
The following variables were assessed: age, gender, type of health insurance, comorbidity on admission, Charlson comorbidity index, (20) diagnosis leading to hospitalization, surgical procedure performed, detection event, source of information of the REUE.
Data including demographic data, vital signs, comorbidity, cause of hospitalization, length of stay in the ICU, prior antibiotic use, mechanical ventilation, source of infection, in-hospital mortality rates, APACHE II, SOFA and Charlson comorbidity index scores were recorded.
We controlled for overall clinical severity by calculating the Charlson comorbidity index (CCI), with higher scores indicating greater comorbidity (Deyo, Cherkin, and Ciol 1992; Klabunde et al.
This study investigated patient characteristics and comorbidities influencing post-RC eGFR at postoperative 3rd month, and ASA Score, ECOG Performance Score, Charlson Comorbidity Index, and the presence of DM, HT, and other comorbidities were found to have no effect on postoperative eGFR.
After the researchers controlled for age, vaccine type, treatment type in the 3 months prior to vaccination and during the study period, Charlson comorbidity index, and RA duration, the only significant predictors of vaccine seroresponse were vaccine dose and age.
Their average Charlson comorbidity index was about 1.3.
Exposure to biologic therapies, methotrexate, and cyclosporine were calculated as cumulative years of exposure, as were other expected confounders such as duration of psoriasis, length of exposure to phototherapy, and the modified Charlson Comorbidity Index. There were data on 579 cancer cases and 2,671 matched controls; this included 41 cases of squamous cell carcinoma and 108 cases of basal cell carcinoma.
Case patients (1,417), defined as those who died of an opioid-related cause, were matched with up to four controls based on age, sex, index year, history of chronic kidney disease, and Charlson comorbidity index (5,097 participants).